Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Video Abstract Image.AcneFeatured ArticlesLatest NewsSkincareThe Latest
July 24, 2025

JDD Recent Video Abstract Picks

Did You Miss These?   Missed any of our recent Video Abstracts? Catch up now! A Scientific Approach to Defining, Evaluating, and Treating Pre-Aging With a Cosmetic Regimen Containing a…
Journal of Drugs in Dermatology JDD Article About Botulinum Toxin in Hidradenitis Suppurativa: A Systematic ReviewFeatured ArticlesHidradenitis SuppurativaLatest NewsThe Latest
July 23, 2025

Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review

Botulinum Toxin for Hidradenitis Suppurativa? Early Evidence Looks Promising Hidradenitis suppurativa  (HS) remains a challenging and often painful condition—one that disproportionately affects women, people of color, and underserved populations. With…
Journal of Drugs in Dermatology JDD Author Spotlight featuring Natalia N. Khosla MD.AlopeciaAuthor SpotlightDerm CommunityFeatured ArticlesLatest NewsThe Latest
July 22, 2025

July Author Spotlight

Author Spotlight: Dr. Natalia Neha Khosla on Health Equity, Inflammation, and Innovation in Dermatology July’s JDD Author Spotlight  features Natalia Neha Khosla, MD MSc, author of the July article, “Socioeconomic…

Leave a Reply